Pubblicazioni

2022

• Derchi G, Musallam KM, Pinto VM, Graziadei G, Giuditta M, Barella S, Origa R, Casu G, Pasanisi A, Longo F, Casale M, Miceli R, Merella P, Gianesin B, Ameri P, Tartaglione I, Perrotta S, Piga A, Cappellini MD, Forni GL. Tricuspid-valve regurgitant jet velocity as a risk factor for death in β-thalassemia. Haematologica. 2022 Jul 1;107(7):1714-1718.
• Lopes LR, Losi MA, Sheikh N, Laroche C, Charron P, Gimeno J, Kaski JP, Maggioni AP, Tavazzi L, Arbustini E, Brito D, Celutkiene J, Hagege A, Linhart A, Mogensen J, Garcia-Pinilla JM, Ripoll-Vera T, Seggewiss H, Villacorta E, Caforio A, Elliott PM; Cardiomyopathy Registry Investigators Group. Association Between Common Cardiovascular Risk Factors and Clinical Phenotype in Patients with Hypertrophic Cardiomyopathy From the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis Registry. Eur Heart J Qual Care Clin Outcomes. 2022 Feb 9:qcac006. (Epub ahead of print).
• Pinto VM, Musallam KM, Derchi G, Graziadei G, Giuditta M, Origa R, Barella S, Casu G, Pasanisi A, Longo F, Casale M, Miceli R, Merella P, Tartaglione I, Piga A, Cappellini MD, Gianesin B, Forni GL; Webthal project. Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization. Blood. 2022 Mar 31;139(13):2080-2083.

2021

• Zeymer U, Ludman P, Danchin N, Kala P, Laroche C, Sadeghi M, Caporale R, Shaheen SM, Legutko J, Iakobsishvili Z, Alhabib KF, Motovska Z, Studencan M, Mimoso J, Becker D, Alexopoulos D, Kereseselidze Z, Stojkovic S, Zelveian P, Goda A, Mirrakhimov E, Bajraktari G, Al-Farhan H, Šerpytis P, Raungaard B, Marandi T, Moore AM, Quinn M, Karjalainen PP, Tatu-Chitolu G, Gale CP, Maggioni AP, Weidinger F; ACVC EAPCI EORP ACS STEMI investigators group of the ESC. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. Eur Heart J. 2021 Nov 21;42(44):4536-4549. (Bernabò P)

2020

• De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, Mancone M, Mercuro G, Muscoli S, Nodari S, Pedrinelli R, Sinagra G, Indolfi C; Società Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020 Jun 7;41(22):2083-2088. (Bernabò P).
• Zeymer U, Ludman P, Danchin N, Kala P, Maggioni AP, Weidinger F; ACS STEMI Investigators. The ESC ACCA EAPCI EORP acute coronary syndrome ST-elevation myocardial infarction registry. Eur Heart J Qual Care Clin Outcomes. 2020 Apr 1;6(2):100-104. (Bernabò P).

2019

• De Luca L, Colivicchi F, Meessen J, Uguccioni M, Piscione F, Bernabò P, Lardieri G, Granatelli A, Gabrielli D, Gulizia MM; EYESHOT Post-MI Investigators. How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study. Clin Cardiol. 2019 Nov;42(11):1113-1120.
• Derchi G, Dessì C, Bina P, Cappellini MD, Piga A, Perrotta S, Tartaglione I, Giuditta M, Longo F, Origa R, Quarta A, Pinto V, Forni GL; Webthal®. Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited. Intern Emerg Med. 2019 Apr;14(3):365-370.
• Pepe M, Sardella G, Stefanini GG, Corcione N, Nestola PL, Morello A, Briguori  C, Tamburino C, Fabbiocchi F, Rotolo FL, Tomai F, Paggi A, Lombardi M, Gioffrè G, Sclafani R, Rolandi A, Sciahbasi A, Scardaci F, Signore N, Mancone M, Giordano A. Impact of Insulin-Treated and Noninsulin-Treated Diabetes Mellitus in All-Comer Patients Undergoing Percutaneous Coronary Interventions With Polymer-Free Biolimus-Eluting Stent (from the RUDI-FREE Registry). Am J Cardiol. 2019 Nov 15;124(10):1518-1527.

2017

• Rossini R, Angiolillo DJ, Musumeci G, Capodanno D, Lettino M, Trabattoni D, Pilleri A, Calabria P, Colombo P, Bernabò P, Ferlini M, Ferri M, Tarantini G, De Servi S, Savonitto S. Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: Results of the surgery after stenting registry. Catheter Cardiovasc Interv. 2017 Jan;89(1):E13-E25.

2016

• Cecconi M, Parodi MI, Formisano F, Spirito P Autore C, Musumeci MB, Favale S, Forleo C, Rapezzi C, Biagini E, Davì S, Canepa E, Pennese L, Castagnetta M, Degiorgio D, Coviello DA. Targeted next-generation sequencing helps to decipher the genetic and phenotypic heterogeneity of hypertrophic cardiomyopathy. Int J Mol Med. 2016 Oct;38(4):1111-24.
• Elliott P, Charron P, Blanes JR, Tavazzi L, Tendera M, Konté M, Laroche C,Maggioni AP; EORP Cardiomyopathy Registry Pilot Investigators. European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. Eur Heart J. 2016 Jan 7;37(2):164-73. (Devoto, E.)
• Maron BJ, Spirito P. Surgical Ventricular Septal Myectomy in the Developing World. Am J Cardiol. 2016 Mar 1;117(5):874-7.
• Rossini R, Angiolillo DJ, Musumeci G, Capodanno D, Lettino M, Trabattoni D, Pilleri A, Calabria P, Colombo P, Bernabò P, Ferlini M, Ferri M, Tarantini G, De Servi S, Savonitto S. Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: Results of the surgery after stenting registry. Catheter Cardiovasc Interv. 2016 Jul 12.
• Spirito P, Ferrazzi P. The challenge of diagnosing hypertrophic cardiomyopathy in patients of African descent. Heart. 2016 Sep 27. pii: heartjnl-2016-310361
• Spirito P, Ferrazzi P. Pulmonary hypertension in hypertrophic cardiomyopathy: a forgotten marker in the identification of candidates to surgical myectomy? Eur Heart J Cardiovasc Imaging. 2016 Jun;17(6):611-2.

2015

• Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P,  Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl  J Med. 2015 May 7;372(19):1791-800.
• Chan RH, Maron BJ, Olivotto I, Assenza GE, Haas TS, Lesser JR, Gruner C, Crean AM, Rakowski H, Rowin E, Udelson J, Lombardi M, Tomberli B, Spirito P, Formisano  F, Marra MP, Biagini E, Autore C, Manning WJ, Appelbaum E, Roberts WC, Basso C, Maron MS. Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 May 8. pii: S0002-9149(15)01258-8.
• Elliott P, Charron P, Blanes JR, Tavazzi L, Tendera M, Konté M, Laroche C, Maggioni AP; EORP Cardiomyopathy Registry Pilot Investigators. European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. Eur Heart J. 2016 Jan 7;37(2):164-73. (Devoto E)
• Ferrazzi P, Spirito P, Iacovoni A, Calabrese A, Migliorati K, Simon C, Pentiricci S, Poggio D, Grillo M, Amigoni P, Iascone M, Mortara A, Maron BJ, Senni M, Bruzzi P. Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy. J Am Coll Cardiol. 2015 Oct 13;66(15):1687-96.
• Maron BJ, Spirito P. Surgical Ventricular Septal Myectomy in the Developing World. Am J Cardiol. 2016 Mar 1;117(5):874-7. Epub 2015 Dec 13.
• Pennacchini E, Musumeci MB, Conte MR, Stöllberger C, Formisano F, Bongioanni S, Francia P, Volpe M, Autore C. Electrocardiographic evolution in patients with  hypertrophic cardiomyopathy who develop a left ventricular apical aneurysm. J Electrocardiol. 2015 Jun 4. pii: S0022-0736(15)00185-5.
• Pinto V, Balocco M, Ambaglio I, Derchi G, Malcovati L, Forni GL. Iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy. Clin Case Rep. 2015 Nov;3(11):952-4.
• Spirito P. The dawn of a better day for patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015 May 12;65(18):1929-30.

2014

• Biagini E, Olivotto I, Iascone M, Parodi MI, Girolami F, Frisso G, Autore C, Limongelli G, Cecconi M, Maron BJ, Maron MS, Rosmini S, Formisano F, Musumeci B,  Cecchi F, Iacovoni A, Haas TS, Bacchi Reggiani ML, Ferrazzi P, Salvatore F, Spirito P, Rapezzi C. Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. Am J Cardiol. 2014 Sep 1;114(5):769-76.
• Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Prognostic value  of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic  cardiomyopathy. Circulation. 2014 Aug 5;130(6):484-95.
• Derchi G, Balocco M, Bina P, Caruso V, D'Ascola DG, Littera R, Origa R, Cappellini MD, Forni GL. Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up. Haematologica. 2014 Feb;99(2):e17-8.
• Derchi G, Galanello R, Bina P, Cappellini MD, Piga A, Lai ME, Quarta A, Casu G, Perrotta S, Pinto V, Musallam KM, Forni GL; Webthal Pulmonary Arterial Hypertension Group*. Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation. 2014 Jan 21;129(3):338-45.
• Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014 Jul 8;64(1):83-99. doi: 10.1016/j.jacc.2014.05.003. Review. Erratum in: J Am Coll Cardiol. 2014 Sep 16;64(11):1188.
• Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Reply: obstructive sleep apnea and hypertrophic cardiomyopathy: obiter dictum or more? J Am Coll Cardiol. 2014 Dec 16;64(23):2562.
• Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS, Bongioanni S, Semsarian C, Devoto E, Musumeci B, Lai F, Yeates L, Conte MR, Rapezzi C, Boni  L, Maron BJ. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014 May 1;113(9):1550-5.
• Spirito P, Autore C, Maron BJ. Reply. Am J Cardiol. 2014 Aug 1;114(3):501.

2013

• Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Mark Estes NA 3rd, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with  hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. Heart Rhythm. 2013 Feb;10(2):214-8.
• Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni  L, Berger S, Maron MS, Link MS. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Apr 9;61(14):1527-35.
• Rossini R, Capodanno D, Lettieri C, Musumeci G, Limbruno U, Molfese M, Spatari V, Calabria P, Romano M, Tarantini G, Gavazzi A, Angiolillo DJ. Long-term outcomes of patients with acute coronary syndrome and nonobstructive coronary artery disease. Am J Cardiol. 2013 Jul 15;112(2):150-5.
  
  

2012

• Baldasseroni S, Urso R, Maggioni AP, Orso F, Fabbri G, Marchionni N, Tavazzi L; IN-CHF Investigators. Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: Data from the IN-CHF Registry. Nutr Metab Cardiovasc Dis. 2012 May;22(5):442-8. (Derchi G)
• Iacovoni A, Spirito P, Simon C, Iascone M, Di Dedda G, De Filippo P, Pentiricci S, Boni L, Senni M, Gavazzi A, Ferrazzi P. A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur Heart J. 2012 Aug;33(16):2080-7.
• Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29;367(22):2089-99. (Bernabò P)
• Todiere G, Aquaro GD, Piaggi P, Formisano F, Barison A, Masci PG, Strata E, Bacigalupo L, Marzilli M, Pingitore A, Lombardi M. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2012 Sep 4;60(10):922-9.

2011

• Derchi G, Formisano F, Balocco M, Galanello R, Bina P, Dessì C, Piga A, Donato G, Cappellini MD, Cassinerio E, Quarta G, Melpignano A, Forni GL. Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study. Eur J Echocardiogr. 2011 Mar;12(3):242-6.
• Musumeci MB, Spirito P, Cauti FM, Autore C. High risk for sudden death identified by electrocardiographic loop recording in a patient with hypertrophic cardiomyopathy without major risk factors. Am J Cardiol. 2011 May15;107(10):1558-60.
• Musumeci B, Spirito P, Parodi MI, Assenza GE, Autore C. Congenital accessory mitral valve tissue anomaly in a patient with genetically confirmed hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2011 May;24(5):592.e5-6.

2010

• Aquaro GD, Masci P, Formisano F, Barison A, Strata E, Pingitore A, Positano V, Spirito P, Lombardi M. Usefulness of delayed enhancement by magnetic resonance imaging in hypertrophic cardiomyopathy as a marker of disease and its severity. Am J Cardiol. 2010 Feb 1;105(3):392-7.
• Aquaro GD, Positano V, Pingitore A, Strata E, Di Bella G, Formisano F, Spirito P, Lombardi M. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2010 Apr 7;12:21.
• Baldasseroni S, Orso F, Fabbri G, De Bernardi A, Cirrincione V, Gonzini L, Fumagalli S, Marchionni N, Midi P, Maggioni AP; Italian Network on Congestive Heart Failure Investigators. Age-dependent prognostic significance of atrial fibrillation in outpatients with chronic heart failure: data from the Italian Network on Congestive Heart Failure Registry. Cardiology. 2010 Jul;116(2):79-88. (Derchi G)
• Derchi G, Lai ME, Marcaccini P, Carta MP, Vacquer S. Human immunodeficiency virus and beta-thalassemia major: A "competition of guilt" for pulmonary arterial hypertension. Report of a case and a review of the literature. Hemoglobin. 2010;34(1):61-6. Review.
• Maines M, Landolina M, Lunati M, Lonardi G, Pappone A, Proclemer A, Zanotto G, Santini M, Varbaro A, Vimercati M, Valsecchi S; Italian Clinical Service Optivol-CRT Group. Intrathoracic and ventricular impedances are associated with changes in ventricular volume in patients receiving defibrillators for CRT. Pacing Clin Electrophysiol. 2010 Jan;33(1):64-73. (Molini D)
• Ribichini F, Ansalone G, Bartorelli A, Beqaraj F, Berni A, Colangelo S, D'Amico M, Della Rovere F, Fiscella A, Gabrielli G, Indolfi C, La Vecchia L, Loschiavo P, Marinoni G, Marzocchi A, Milazzo D, Romano M, Sangiorgio P, Sheiban I, Tamburino C, Tuccillo B, Villani R, Cappi B, Quijada MJ, Vassanelli C; EXECUTIVE Trial Investigators. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease. Study design and rationale of the EXECUTIVE trial. J Cardiovasc Med (Hagerstown). 2010 Apr;11(4):299-309. (Rolandi A.)
• Spirito P, Boriani G. Device therapy: a subcutaneous ICD--preliminary results.Nat Rev Cardiol. 2010 Oct;7(10):543-4.

2009

• Assenza GE, Spirito P, Musumeci MB, Lombardi M, Quarta G, Autore C.
  Severe left ventricular wall thinning and extensive fibrosis without evolution to end stage disease in a patient with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2009 Oct;22(10):1196.e1-2.

• Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F, Lorenzini M, Terzi F, Bacchi-Reggiani L, Boriani G, Branzi A, Boni L, Rapezzi C.
  Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol. 2009 Dec 15;104(12):1727-31

• Bongioanni S, Spirito P, Masi AS, Chiribiri A, Bonamini R, Conte MR.
  Extensive myocardial fibrosis in a patient with hypertrophic cardiomyopathy and ventricular tachycardia without traditional high-risk features. Circ Cardiovasc Imaging. 2009 Jul;2(4):349-50.
• Catanzariti D, Lunati M, Landolina M, Zanotto G, Lonardi G, Iacopino S, Oliva F, Perego GB, Varbaro A, Denaro A, Valsecchi S, Vergara G; Italian Clinical Service Optivol-CRT Group.
  Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure.Pacing Clin Electrophysiol. 2009 Mar;32(3):363-70.

• Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB, Almquist AK, Baffa JM, Saul JP, Ho CY, Seidman J, Seidman CE.
  Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA. 2009 Mar 25;301(12):1253-9.
• Maron BJ, Semsarian C, Shen WK, Link MS, Epstein AE, Estes NA 3rd, Almquist A, Giudici MC, Haas TS, Hodges JS, Spirito P.
  Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. Heart Rhythm. 2009 May;6(5):599-602.
• Maron BJ, Spirito P.
  [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM]. Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Apr;37(4):297-302. Chinese.
• Pepe A, Positano V, Capra M, Maggio A, Pinto CL, Spasiano A, Forni G, Derchi G, Favilli B, Rossi G, Cracolici E, Midiri M, Lombardi M.
  Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart. 2009 Oct;95(20):1688-93.
• Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators.
  Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009 Dec;158(6):896-901.e3.
• Spirito P, Autore C, Rapezzi C, Bernabò P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, Estes NA, Barillà CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ.
  Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009 Apr 7;119(13):1703-10.
• Spirito P, Maron BJ.
  [Risk stratification for sudden death in hypertrophic cardiomyopathy]. Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Apr;37(4):294-7. Chinese.

2008

• Biagini E, Spirito P, Leone O, et all. Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol. 2008 Feb 1;101(3):387-92
• Maron BJ, Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2008 Oct;19(10):1118-26
• Elliott P, Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice. Heart. 2008 Oct;94(10):1269-75. Review
• Cogliandro T, Derchi G, Mancuso L, et all; Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE). Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med (Hagerstown). 2008 May;9(5):515-25
• Ramazzotti A, Pepe A, Positano V, Scattini B, Santarelli MF, Landini L, De Marchi D, Keilberg P, Derchi G, Formisano F, Pili M, Lai ME, Forni G, et all. Standardized T2* map of a normal human heart to correct T2* segmental artefacts; myocardial iron overload and fibrosis in thalassemia intermedia versus thalassemia major patients and electrocardiogram changes in thalassemia major patients. Hemoglobin. 2008;32(1-2):97-107
• Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, Sangiorgio P, Zoccai GB; DESSERT Investigators. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol. 2008 Jun 1;101(11):1560-6

2007

• Maron BJ, Spirito P, Shen W-K, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP MD, Thorsten Lawrenz T, Boriani GD, Estes III NAM, Favale S, Piccininno M, Winters SL, Santini M, MD, Betocchi S, MD, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Prevention of sudden cardiac death and selection of patients for implantable cardioverter-defibrillators in hypertrophic cardiomyopathy. JAMA 2007;298:405-12
• Spirito P, Autore C. Apical hypertrophic cardiomyopathy or left ventricular noncompaction? A difficult differential diagnosis. Eur Heart J 2007;28:1923-24
• Cha Y-M, Gersh BJ, Maron BJ, Boriani G, Spirito P, Hodge DO, Weivoda PL, Trusty JM, Friedman PA, Hammill SC, Rea RF, Shen W-K. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovascular Electrophysiology 2007; 18:483-7
• Derchi G. et al. Eelectrocardiographic changes in thalassemia major patients: correlations with myocardial iron overload and myocardial fibrosis. Journal of Cardiovascular Magnetic Resonance 2007 p. 167 Vol 9; N.2

2006

• Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ.  Prevalence, clinical profile and significance of the end-stage phase in a large hypertrophic cardiomyopathy cohort.
  Circulation. 2006;114:216-25
• Spirito P, Autore C.
  Management of hypertrophic cardiomyopathy.
  British Medical Journal. 2006;332:1251-55
• Mazzotta G.: Il ruolo della proteina C reattiva nelle strategie di prevenzione
  cardiovascolare. Monaldi Arch. Chest Dis 2006; 1, suppl. 2, 55
• Capuano V, Mazzotta G.: The third component of the complement (C3) is a marker of the risk of atherogenesis.
  European Journal of Cardiovascular Prevention and Rehabilitation, 13:658-660, 2006

2005

• Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005 Jan 27;352(4):362-72
• Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005 Apr 5;45(7):1076-80
• JambriK Z, Derchi G, et al Lack of prognostic value of normalized integrated backscatter analysis of myocardium in patients with thalassemia major: a long-term follow-up study. Echocardiography 2005 Mar;22(3):239-44
• Derchi G et al. Efficacy and safety of sildenafil in the treatment of severepulmonary hypertension in patients with hemoglobinopathies. Haematologica2005 Apr;90(4):452-8
• Derchi et al. LINEE GUIDA PER LE COMPLICANZE CARDIACHE NELLA TALASSEMIA MAJOR Idelson-Gnocchi editori
• Derchi G et al. Incidence of Pulmonary Hypertension in Haemoglobinopathic Patients without Left Ventricular Dysfunction.  Blood,106(11), November 16, 2005
• Derchi G, Forni GL. Therapeutic Approaches to Pulmonary Hypertension in Hemoglobinopathies. Efficacy and Safety of Sildenafil in the Treatment of Severe Pulmonary Hypertension in Patients with Hemoglobinopathy. Ann. N.Y. Acad. Sci. 1054: 471-475 (2005). © 2005 New York Academy of Sciences
• Grupo de Trabajo y Comitè ESC (G. Mazzotta en Comitè y Coordinador de revision de las CPG):Guias de Practica Clinica sobre el diagnostico y tratamiento de la hipertension arterial pulmonar. Rev. Esp. Cardiol 58, 523, 2005
• G. Mazzotta, S. Pirelli, M. Guazzi, A Barsotti.  Programma di aggiornamento della Federazione Italiana di Cardiologia; 6 fascicoli nel 2005. Centro Scientifico Editore, Torino
• Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin YLopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K; ESC Committe for Practice Guideline (CPG).  Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology Eur Heart J. 2005 Feb;26(4):384-416
• Derchi G et al Prognostic value of the Atrial Natriuretic Peptide in Asymptomatic Patients with Beta-Thalassemia Major: a ten year follow-up JCM in press

2004

• Boriani G, Maron BJ, Shen WK, Spirito P.  Prevention of sudden death in hypertrophic cardiomyopathy: but which defibrillator for which patient? Circulation. 2004 Oct 12;110(15):e438-42
• Boriani G, Biffi M, Rapezzi C, Coccolo F, Branzi A, Spirito P. Ventricular fibrillation during sleep in an adolescent with hypertrophic cardiomyopathy: the difficulty of risk stratification and the power of the cardioverter defibrillator. Int J Cardiol. 2004 Oct;97(1):143-4
• Autore C, Spirito P. Approach to Hypertrophic Cardiomyopathy. Curr Treat Options Cardiovasc Med. 2004 Dec;6(6):489-498